Pradaxa 50 mg Oral Pellet
RxNorm 2590637
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2590637 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Pradaxa 50 mg Oral Pellet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Dabigatran etexilate 50 mg Oral Pellet [Pradaxa]
(Atom ID: 12722310)
PSNPrescribable
Prescribable Name (PSN):
Pradaxa 50 mg Oral Pellet
(Atom ID: 12722312)
SYPrescribable
Synonym (SY):
Pradaxa 50 mg Oral Pellet
(Atom ID: 12722311)
Patient Education
Dabigatran
Dabigatran is used to treat deep vein thrombosis (DVT; a blood clot, usually in the leg) and pulmonary embolism (PE; a blood clot in the lung) in adults and children 3 months of age and older who have been treated with an injectable anticoagulant ('blood thinner'). It is also used to reduce the risk of a DVT and PE from happening again after initial treatment is completed in adults and children 3 months of age and older. Dabigatran is used to help prevent DVT and PE in adults who have had hip replacement surgery. Dabigatran is also used to help prevent strokes or serious blood clots in adults who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body, and possibly causing strokes) without heart valve disease. Dabigatran is in a class of anticoagulant medications called direct thrombin inhibitors. It works by preventing blood clots from forming in the body.
[Learn More]
* Please review the disclaimer below.